Scott Lunin is a partner in the Corporate Practice Group. His practice focuses on advising domestic and foreign issuers and investment banks in capital market transactions, corporate governance and public company counseling, with a particular emphasis on the life sciences and technology industries. Mr. Lunin has successfully represented clients in a wide range of complex capital markets transactions, including initial public offerings, follow-on equity offerings, PIPEs and senior debt offerings.

Mr. Lunin regularly advises life sciences companies on financing transactions, SEC reporting and disclosure requirements, stock exchange requirements and corporate governance issues. He also advises emerging companies on a variety of matters, including venture capital financings.

In recent years, Mr. Lunin has advised Schrödinger, Dyne Therapeutics, Decibel Therapeutics, Nabriva Therapeutics and Summit Therapeutics on their initial public offerings. He has also advised investment banks on the initial public offerings of Theseus Pharmaceuticals, TCR2 Therapeutics and Entasis Therapeutics. 

Before joining WilmerHale, Mr. Lunin was a senior attorney at IBM where he advised on a variety of corporate and securities matters. Prior to attending law school, Mr. Lunin served as an intelligence officer with the Defense Intelligence Agency.

Mr. Lunin serves on Law360's Capital Markets Advisory Board. 

Insights & News


  • Education

    • JD, Georgetown University Law Center, 2009

      cum laude Notes Editor, The Georgetown Law Journal
    • BA, International Affairs, The George Washington University, 2003

      magna cum laude Phi Beta Kappa
  • Admissions

    • New York



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.